{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T20:31:03Z","timestamp":1773865863194,"version":"3.50.1"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,3,19]],"date-time":"2015-03-19T00:00:00Z","timestamp":1426723200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s40265-015-0372-3","type":"journal-article","created":{"date-parts":[[2015,3,18]],"date-time":"2015-03-18T19:21:42Z","timestamp":1426706502000},"page":"473-485","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Drug Therapy of Apparent Treatment-Resistant Hypertension: Focus on Mineralocorticoid Receptor Antagonists"],"prefix":"10.1007","volume":"75","author":[{"given":"Daniel","family":"Glicklich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,3,19]]},"reference":[{"key":"372_CR1","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.ahj.2014.02.008","volume":"167","author":"S Vemulapalli","year":"2014","unstructured":"Vemulapalli S, Ard J, Bakris GL, Bhatt DL, et al. Proceedings from Duke resistant hypertension think tank. Am Heart J. 2014;167:775\u201388. doi: 10.1016\/j.ahj.2014.02.008 .","journal-title":"Am Heart J."},{"issue":"34","key":"372_CR2","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.semnephrol.2014.04.002","volume":"2014","author":"J Vega","year":"2014","unstructured":"Vega J, Bisognano JD. The prevalence, incidence, prognosis and associated conditions of resistant hypertension. Semin Nephrol. 2014;2014(34):247\u201356. doi: 10.1016\/j.semnephrol.04.002 .","journal-title":"Semin Nephrol."},{"key":"372_CR3","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S0140-6736(09)60566-3","volume":"373","author":"H Krum","year":"2009","unstructured":"Krum H, Schlaich M, Whitboum R, Sobotka P, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicenter safety and proof of principle cohort study. Lancet. 2009;373:1275\u201381. doi: 10.1016\/S0140-6736(09)60566-3 .","journal-title":"Lancet."},{"key":"372_CR4","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(10)62039-9","volume":"376","author":"MD Esler","year":"2010","unstructured":"Esler MD, Krum H, Sobotka PA, Schlaich MP, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 trial): a randomized controlled trial. Lancet. 2010;376:1903\u20139. doi: 10.1061\/S0140-6736(10)62039-9 .","journal-title":"Lancet."},{"key":"372_CR5","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1161\/CIRCULATIONAHA.113.005405","volume":"129","author":"V Papademetriou","year":"2014","unstructured":"Papademetriou V, Rashidi AA, Tsioufis C, Doumis M. Renal nerve ablation for resistant hypertension: how did we get here, present status and future directions. Circulation. 2014;129:1440\u201351. doi: 10.1161\/CIRCULATIONAHA.113.005405 .","journal-title":"Circulation"},{"key":"372_CR6","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJMoa1402670","volume":"370","author":"DL Bhatt","year":"2014","unstructured":"Bhatt DL, Kandzari DE, O\u2019Neill WW, D\u2019Agostino R, Flack JM, Katzen BT, et al. SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393\u2013401. doi: 10.1056\/NEJMoa1402670 .","journal-title":"N Engl J Med."},{"key":"372_CR7","first-page":"95","volume":"15","author":"HC Patel","year":"2014","unstructured":"Patel HC, Hayward C, Di Mario C. Symplicity HTN 3: the death knell for renal denervation in hypertension? Glob Cardiol Sci Prac. 2014;15:95\u20138. doi: 10.5339\/gcsp.2014.15 .","journal-title":"Glob Cardiol Sci Prac."},{"key":"372_CR8","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s11906-013-0363-2","volume":"15","author":"C Ukena","year":"2013","unstructured":"Ukena C, Mahfoud F, Ewen S, Cremers B, et al. Renal denervation in the treatment of hypertension. Curr Hypertens Rep. 2013;15:363\u20139. doi: 10.1007\/s11906-013-0363-2 .","journal-title":"Curr Hypertens Rep."},{"key":"372_CR9","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1161\/CIRCULATIONAHA.108.189141","volume":"117","author":"DA Calhoun","year":"2008","unstructured":"Calhoun DA, Jones D, Textor S, Goff DC, et al. Resistant hypertension: diagnosis, evaluation, and treatment. Circulation. 2008;117:e510\u201326. doi: 10.1161\/CIRCULATIONAHA.108.189141 .","journal-title":"Circulation."},{"issue":"11","key":"372_CR10","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1001\/archinte.168.11.1159","volume":"168","author":"KK Gaddam","year":"2008","unstructured":"Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, Pimenta E, et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone and persistent intravascular volume expansion. Arch Intern Med. 2008;168(11):1159\u201364.","journal-title":"Arch Intern Med."},{"key":"372_CR11","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.cjca.2012.03.010","volume":"28","author":"D Clark","year":"2012","unstructured":"Clark D, Ahmed MI, Calhoun DA. Resistant hypertension and aldosterone: an update. Can J Cardiol. 2012;28:318\u201325. doi: 10.1016\/j.cjca.2012.03.010 .","journal-title":"Can J Cardiol."},{"key":"372_CR12","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","volume":"289","author":"AV Chobanian","year":"2003","unstructured":"Chobanian AV, Bakris GL, Black HR, Cushman WC, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560\u201372.","journal-title":"JAMA."},{"issue":"21","key":"372_CR13","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1001\/jama.2014.5180","volume":"311","author":"W Vongpatanasin","year":"2014","unstructured":"Vongpatanasin W. Resistant hypertension- a review of diagnosis and management. JAMA. 2014;311(21):2216\u201324. doi: 10.1001\/jama.2014.5180 .","journal-title":"JAMA."},{"key":"372_CR14","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1161\/HYPERTENSIONAHA.112.192096","volume":"60","author":"SL Daughtery","year":"2012","unstructured":"Daughtery SL, Powers JD, Magid DJ, Masoudi FA, et al. The association between medical adherence and treatment intensification with blood pressure control in resistant hypertension. Hypertension. 2012;60:303\u20139. doi: 10.1161\/HYPERTENSIONAHA.112.192096 .","journal-title":"Hypertension."},{"key":"372_CR15","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1097\/HJH.0b013e32835e2286","volume":"31","author":"O Jung","year":"2013","unstructured":"Jung O, Gechter JL, Wunder C, Paulke A, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens. 2013;31:766\u201374. doi: 10.1097\/HJH.0b013e32835e2286 .","journal-title":"J Hypertens."},{"key":"372_CR16","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1097\/HJH.0b013e3283652c61","volume":"31","author":"B Strauch","year":"2013","unstructured":"Strauch B, Petrak O, Zelinka T, Rosa J, et al. Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. J Hypertens. 2013;31:2455\u201361. doi: 10.1097\/HJH.0b013e3283652c6116 .","journal-title":"J Hypertens."},{"key":"372_CR17","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1161\/HYPERTENSIONAHA.110.168948","volume":"57","author":"A Sierra De la","year":"2011","unstructured":"De la Sierra A, Segura J, Banegas JR, Gorostidi M, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011;57:898\u2013902. doi: 10.1161\/HYPERTENSIONAHA.110.168948 .","journal-title":"Hypertension"},{"key":"372_CR18","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1001\/archinte.168.21.2340","volume":"168","author":"FG Salles","year":"2008","unstructured":"Salles FG, Cardoso CRL, Muxfeldt ES. Prognostic influence of office and ambulatory blood pressure in resistant hypertension. Arch Intern Med. 2008;168:2340\u20136.","journal-title":"Arch Intern Med."},{"key":"372_CR19","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.amjhyper.2005.05.014","volume":"18","author":"SD Perdomenico","year":"2005","unstructured":"Perdomenico SD, Lapenna D, Buicci A, Tommaso R, et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant and true resistant hypertension. Am J Hypertens. 2005;18:1422\u20138. doi: 10.1016\/j.amjhyper.2005.05.014 .","journal-title":"Am J Hypertens."},{"key":"372_CR20","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.semnephrol.2014.04.004","volume":"34","author":"BM Egan","year":"2014","unstructured":"Egan BM, Li J. Role of aldosterone blockade in resistant hypertension. Semin Nephrol. 2014;34:273\u201384. doi: 10.1016\/j.semnephrol.2014.04.004 .","journal-title":"Semin Nephrol."},{"key":"372_CR21","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/j.1751-7176.2012.00653.x","volume":"14","author":"O Bakhtar","year":"2012","unstructured":"Bakhtar O, Ference BA, Hedquist LA, Levy PA, et al. Relationship of resistant hypertension and treatment outcomes with total arterial compliance in a predominantly African American hypertensive cohort. J Clin Hypertens. 2012;14:618\u201322. doi: 10.1111\/j.1751-7176.2012.00653.x .","journal-title":"J Clin Hypertens."},{"key":"372_CR22","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/HJH.0b013e32835b6be7","volume":"31","author":"D Shimbo","year":"2013","unstructured":"Shimbo D, Levitan EB, Booth JN, Calhoun DA, et al. The contributions of unhealthy lifestyle factors to apparent resistant hypertension: findings from the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study. J Hypertens. 2013;31:370\u20136. doi: 10.1097\/HJH.0b013e32835b6be7 .","journal-title":"J Hypertens."},{"key":"372_CR23","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/01.HYP.35.5.1135","volume":"35","author":"K Masuo","year":"2000","unstructured":"Masuo K, Mikami H, Ogihara T, Tuck ML. Weight gain-induced blood pressure elevation. Hypertension. 2000;35:1135\u201340. doi: 10.1161\/01.HYP.35.5.1135 .","journal-title":"Hypertension."},{"issue":"3","key":"372_CR24","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/jama.2009.2014","volume":"303","author":"KM Flegal","year":"2010","unstructured":"Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults 1999\u20132008. JAMA. 2010;303(3):235\u201341.","journal-title":"JAMA."},{"key":"372_CR25","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/jch.12049","volume":"15","author":"L Landsberg","year":"2013","unstructured":"Landsberg L, Aronne LJ, Beilin LJ, Burke V, et al. Obesity-related hypertension: pathogenesis, cardiovascular risk and treatment. J Clin Hypertens. 2013;15:14\u201333. doi: 10.111\/jch.12049 .","journal-title":"J Clin Hypertens."},{"issue":"34","key":"372_CR26","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.semnephrol.2014.04.009","volume":"2014","author":"C Flynn","year":"2014","unstructured":"Flynn C. Increased aldosterone: mechanism of hypertension in obesity. Semin Nephrol. 2014;2014(34):340\u20138. doi: 10.1016\/j.semnephrol.2014.04.009 .","journal-title":"Semin Nephrol."},{"key":"372_CR27","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s11906-008-0042-x","volume":"10","author":"TL Goodfriend","year":"2008","unstructured":"Goodfriend TL. Obesity, sleep apnea, aldosterone and hypertension. Curr Hypertens Rep. 2008;10:222\u20136.","journal-title":"Curr Hypertens Rep."},{"key":"372_CR28","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1097\/HJH.0b013e32833b9c63","volume":"28","author":"L Lozano","year":"2010","unstructured":"Lozano L, Tovar JL, Sampol G, Romero O, et al. Continuous positive airway pressure treatment in sleep apnea patients with resistant hypertension; a randomized control trial. J Hypertens. 2010;28:2161\u20138. doi: 10.1097\/HJH.0b013e32833b9c63 .","journal-title":"J Hypertens."},{"key":"372_CR29","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1161\/HYPERTENSIONAHA.111.179788","volume":"58","author":"RP Pedrosa","year":"2011","unstructured":"Pedrosa RP, Drager LF, Gonzaga CC, Sousa MG, et al. Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension. Hypertension. 2011;58:811\u20137. doi: 10.1161\/HYPERTENSIONAHA.111.179788 .","journal-title":"Hypertension."},{"key":"372_CR30","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/jhh.2011.47","volume":"26","author":"T Dudenbostal","year":"2012","unstructured":"Dudenbostal T, Calhoun DA. Resistant hypertension, obstructive sleep apnea and aldosterone. J Human Hypertens. 2012;26:281\u20137. doi: 10.1038\/jhh.2011.47 .","journal-title":"J Human Hypertens."},{"key":"372_CR31","doi-asserted-by":"crossref","unstructured":"Martinez-Garcia MA, Capote F, Campos-Rodriguez F, Oberes P, et al. Effect of CPAP on blood pressure in patients with obstructive sleep apnea and resistant hypertension; the HIPARCO randomized clinical trial. JAMA. 2013;310(22):2407\u201315. doi: 10.1001\/jama.2013.281250 .","DOI":"10.1001\/jama.2013.281250"},{"key":"372_CR32","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.semnephrol.2014.04.003","volume":"34","author":"HJ Androgue","year":"2014","unstructured":"Androgue HJ, Madias NE. The impact of sodium and potassium on hypertension risk. Semin Nephrol. 2014;34:257\u201372. doi: 10.1016\/j.semnephrol.2014.04.003 .","journal-title":"Semin Nephrol."},{"key":"372_CR33","first-page":"307","volume":"34","author":"JS Hirsch","year":"2014","unstructured":"Hirsch JS, Drexler Y, Bomback AS. Aldosterone blockade in chronic kidney disease. SeminNephrol. 2014;34:307\u201322. doi: 10.1016\/j.semnephrol.2014.04.006 .","journal-title":"SeminNephrol."},{"key":"372_CR34","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s11906-007-0066-7","volume":"9","author":"E Pimenta","year":"2007","unstructured":"Pimenta E, Calhoun DA. Resistant hypertension and aldosteronism. Curr Hypertens Rep. 2007;9:353\u20139.","journal-title":"Curr Hypertens Rep."},{"key":"372_CR35","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1161\/01.HYP.0000016176.16042.2F","volume":"39","author":"SJ Taler","year":"2002","unstructured":"Taler SJ, Textor SC, Augustine JE. Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension. 2002;39:982\u20138. doi: 10.1161\/.01.HYP.0000016176.16042.2F .","journal-title":"Hypertension."},{"key":"372_CR36","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1161\/HYPERTENSIONAHA.109.141531","volume":"55","author":"I Gaddam","year":"2010","unstructured":"Gaddam I, Corros C, Pimenta E, Ahmed M, et al. Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism; a prospective clinical study. Hypertension. 2010;55:1137\u201342. doi: 10.1161\/HYPERTENSIONAHA.109.141531 .","journal-title":"Hypertension."},{"key":"372_CR37","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.semnephrol.2014.04.005","volume":"34","author":"J Tamargo","year":"2014","unstructured":"Tamargo J, Solini A, Ruilope LM. Comparison of agents that affect aldosterone action. Sem Nephrol. 2014;34:285\u2013306. doi: 10.1016\/j.semnephrol.2014.04.005 .","journal-title":"Sem Nephrol."},{"key":"372_CR38","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/jhh.2012.29","volume":"27","author":"C De Haro Moraes","year":"2013","unstructured":"De Haro Moraes C, Figueiredo VN, de Faria APC, Barbaro NT. High circulating leptin levels are associated with increased blood pressure in uncontrolled resistant hypertension. J Hum Hypertens. 2013;27:225\u201330. doi: 10.1038\/jhh.2012.29 .","journal-title":"J Hum Hypertens."},{"key":"372_CR39","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/hr.2013.92","volume":"36","author":"APC Faria De","year":"2013","unstructured":"De Faria APC, Demarq C, Figueiredo VN, Morales CH, et al. Hypoadiponectinemia and aldosterone excess are associated with lack of blood pressure control in subjects with resistant hypertension. Hypertens Res. 2013;36:1067\u201372. doi: 10.1038\/hr.2013.92 .","journal-title":"Hypertens Res."},{"key":"372_CR40","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/ajh.2011.245","volume":"25","author":"H Shibata","year":"2012","unstructured":"Shibata H, Itoh H. Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension. Am J Hypertens. 2012;25:514\u201323. doi: 10.1038\/ajh.2011.245 .","journal-title":"Am J Hypertens."},{"key":"372_CR41","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/ajh.2010.169","volume":"23","author":"LA Sechi","year":"2010","unstructured":"Sechi LA, Colussi G, Di Fabio A, Catena C. Cardiovascular and renal damage in primary aldosteronism: outcomes after treatment. Am J Hypertens. 2010;23:1253\u201360. doi: 10.1038\/ajh.2010.169 .","journal-title":"Am J Hypertens."},{"key":"372_CR42","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1681\/ASN.2013121258","volume":"25","author":"T Fujita","year":"2014","unstructured":"Fujita T. Mechanism of salt-sensitive hypertension: focus on adrenal and sympathetic nervous systems. J Am Soc Nephrol. 2014;25:1148\u201355. doi: 10.1681\/ASN.2013.12125 .","journal-title":"J Am Soc Nephrol."},{"key":"372_CR43","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1038\/sj.ki.5000378","volume":"69","author":"CS Fox","year":"2006","unstructured":"Fox CS, Larson MG, Hwang SJ, et al. Cross-sectional relations of serum aldosterone and urine sodium excretion to urinary albumin excretion in a community-based sample. Kidney Int. 2006;69:2064\u20139. doi: 10.1038\/sj.ki.5000378 .","journal-title":"Kidney Int."},{"key":"372_CR44","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1159\/000057385","volume":"24","author":"B Cianciaruso","year":"1998","unstructured":"Cianciaruso B, Bellizi V, Minutolo R, et al. Salt intake and renal outcome in patients with progressive renal disease. Miner Electrolyte Metab. 1998;24:296\u2013301. doi: 10.1159\/000057385 .","journal-title":"Miner Electrolyte Metab."},{"key":"372_CR45","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1161\/HYPERTENSIONAHA.107.100701","volume":"51","author":"E Pimenta","year":"2008","unstructured":"Pimenta E, Gaddam KK, Pratt-Ubunama MN, et al. Relation of dietary salt and aldosterone to urinary protein excretion in subjects with resistant hypertension. Hypertension. 2008;51:339\u201344. doi: 10.1161\/HYPERTENSIONAHA.107.100701 .","journal-title":"Hypertension."},{"key":"372_CR46","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/HJH.0b013e32832810ed","volume":"27","author":"PM Jansen","year":"2009","unstructured":"Jansen PM, Jan Danser AH, Imholz BP, van den Meiracker AH. Aldosterone-receptor antagonism in hypertension. J Hypertens. 2009;27:680\u201391. doi: 10.1097\/HJH.Ob013e32832810ed .","journal-title":"J Hypertens."},{"key":"372_CR47","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/S0735-1097(02)02855-3","volume":"41","author":"S Kasama","year":"2003","unstructured":"Kasama S, Toyama T, Kumakura H, Takayama Y, et al. Effect of spironolactone on cardiac sympathic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy. J Am Coll Cardiol. 2003;41:574\u201381. doi: 10.1016\/S0735-1097(02)02855-3 .","journal-title":"J Am Coll Cardiol."},{"key":"372_CR48","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1161\/01.HYP.0000182661.98259.4f","volume":"46","author":"W Chai","year":"2005","unstructured":"Chai W, Garredls IM, de Vries R, Batenburg WW, et al. Nongenomic effects of aldosterone in the human heart: interaction with angiotensin II. Hypertension. 2005;46:701\u20136. doi: 10.1161\/01.HYP.0000182661.98259.4f .","journal-title":"Hypertension."},{"key":"372_CR49","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1097\/HJH.0b013e3282f254d9","volume":"25","author":"DA Lane","year":"2007","unstructured":"Lane DA, Beevers DG. Amiloride 10\u00a0mg is less effective than spironolactone 25\u00a0mg in patients with hypertension resistant to a multidrug regime including an angiotensin-blocking agent. J Hypertens. 2007;25:2515\u20136. doi: 10.1097\/HJH.O6013e3281fc975a .","journal-title":"J Hypertens"},{"key":"372_CR50","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.amjhyper.2004.08.026","volume":"18","author":"A Mahmud","year":"2005","unstructured":"Mahmud A, Feely J. Aldosterone to renin ratio, arterial stiffness, and the response to aldosterone antagonism in essential hypertension. Am J Hypertens. 2005;18:50\u20135. doi: 10.1016\/j.amjhyper.2004.08.026 .","journal-title":"Am J Hypertens"},{"key":"372_CR51","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1056\/NEJMoa035622","volume":"351","author":"L Sjostrom","year":"2004","unstructured":"Sjostrom L, Lindroos AK, Peltonen M, Torgerson J, et al. Lifestyle, diabetes and cardiovascular risk factors 10\u00a0yr after bariatric surgery. N Engl J Med. 2004;351:2683\u201393.","journal-title":"N Engl J Med."},{"issue":"4","key":"372_CR52","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1097\/SLA.0b013e3182a5034b","volume":"258","author":"SA Brethauer","year":"2013","unstructured":"Brethauer SA, Aminian A, Romero-Talamas H, Batayyah E, et al. Can diabetes be surgically cured: long term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus. Ann Surg. 2013;258(4):628\u201337. doi: 10.1097\/SLA.0b013e3182a50346 .","journal-title":"Ann Surg"},{"key":"372_CR53","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.soard.2013.04.001","volume":"9","author":"AE Pontiroli","year":"2013","unstructured":"Pontiroli AE, Alberto M, Paganelli M, Saibene A, et al. Metabolic syndrome, hypertension, and diabetes mellitus after gastric banding; the role of aging and duration of obesity. Surg Obes Relat Dis. 2013;9:894\u2013900. doi: 10.1016\/j.soard.2013.04.001 .","journal-title":"Surg Obes Relat Dis."},{"issue":"24","key":"372_CR54","doi-asserted-by":"crossref","first-page":"14211","DOI":"10.1073\/pnas.2336140100","volume":"100","author":"M Ehrhart-Bornstein","year":"2003","unstructured":"Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, Langenbach J, et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci USA. 2003;100(24):14211\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"372_CR55","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/jhh.2009.96","volume":"24","author":"K Gaddam","year":"2010","unstructured":"Gaddam K, Pimenta E, Thomas SJ, Cofield SS, et al. Spironolactone reduces severity of obstructive sleep apnea in patients with resistant hypertension: a preliminary report. J Hum Hypertens. 2010;24(8):532\u20137. doi: 10.1038\/jhh.2009.9c .","journal-title":"J Hum Hypertens"},{"issue":"61","key":"372_CR56","first-page":"2461","volume":"2013","author":"L Nicola De","year":"2012","unstructured":"De Nicola L, Gabbai FB, Agarwal R, Chiodini P, et al. Prevalence and prognostic role of resistant hypertension in chronic kidney disease patients. J Am Coll Cardiol. 2012;2013(61):2461\u20137. doi: 10.1016\/jack.12.061 .","journal-title":"J Am Coll Cardiol."},{"key":"372_CR57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/kisup.2012.73","volume":"3","author":"Kidney Disease: improving global outcomes (KDIGO) CKD work group","year":"2013","unstructured":"Kidney Disease: improving global outcomes (KDIGO) CKD work group. KDIGO, 2012. Clinical practice guidelines s for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1\u2013150. doi: 10.1038\/K.sup.2012.64-72 .","journal-title":"Kidney Int Suppl."},{"key":"372_CR58","doi-asserted-by":"crossref","first-page":"185","DOI":"10.7326\/0003-4819-159-3-201308060-00008","volume":"159","author":"K Uhlig","year":"2013","unstructured":"Uhlig K, Patel I, Ip S, Kitsios GD, et al. Self-measured blood pressure monitoring in the management of hypertension: a systematic review and meta-analysis. Ann Intern Med. 2013;159:185\u201394.","journal-title":"Ann Intern Med."},{"key":"372_CR59","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1161\/HYPERTENSIONAHA.109.131235","volume":"54","author":"E Pimenta","year":"2009","unstructured":"Pimenta E, Gaddam KK, Oparil S, Aban I, et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension. Hypertension. 2009;54:475\u201381. doi: 10.1161\/HYPERTENSIONAHA.109.131235 .","journal-title":"Hypertension."},{"issue":"5","key":"372_CR60","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","volume":"311","author":"PA James","year":"2014","unstructured":"James PA, Oparil S, Carter BL, Cushman WC, et al. 2014 evidence-based guideline for the management of high blood pressure in adults : report from the panel members appointed to the 8th Joint National Committee (JNC 8). JAMA. 2014;311(5):507\u201320. doi: 10.1001\/jama.2013.284427 .","journal-title":"JAMA."},{"key":"372_CR61","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/HJH.0b013e3281fc975a","volume":"25","author":"G Mancia","year":"2007","unstructured":"Mancia G, De Baker G, Dominiczak A, Cifkova R, et al. Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiology. J Hypertens. 2007;25:1105\u201387. doi: 10.1092\/HJH.06013e3281fc975a .","journal-title":"J Hypertens."},{"key":"372_CR62","first-page":"139","volume":"6","author":"N Kumar","year":"2013","unstructured":"Kumar N, Calhoun DA, Dudenbostel T. Management of patients with resistant hypertension: current treatment options. Integr Blood Press Control. 2013;6:139\u201351.","journal-title":"Integr Blood Press Control"},{"key":"372_CR63","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1056\/NEJMra0907219","volume":"361","author":"ME Ernst","year":"2009","unstructured":"Ernst ME, Moser M. Use of diuretics in patients with hypertension. N Engl J Med. 2009;361:2153\u201364.","journal-title":"N Engl J Med."},{"key":"372_CR64","first-page":"e244","volume":"18","author":"A Brown","year":"2011","unstructured":"Brown A, Captain B. 50 years of thiazides: should thiazide diuretics be considered third-line hypertensive treatment. Am J Hypertens. 2011;18:e244\u201354.","journal-title":"Am J Hypertens."},{"issue":"4","key":"372_CR65","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s12325-013-0020-9","volume":"30","author":"M Gorostidi","year":"2013","unstructured":"Gorostidi M, de la Sierr A. Combination therapy in hypertension. Adv Ther. 2013;30(4):320\u201336. doi: 10.1007\/s12325-013-0020.9 .","journal-title":"Adv Ther."},{"key":"372_CR66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/HYPERTENSIONAHA.110.152892","volume":"56","author":"JM Flack","year":"2010","unstructured":"Flack JM, Sica DA, Bakris G, Brown AL, et al. Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement. Hypertension. 2010;56:1\u201321. doi: 10.1161\/HYPERTENSIONAHA.110.152892 .","journal-title":"Hypertension"},{"key":"372_CR67","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1056\/NEJM198210143071603","volume":"307","author":"Hypertensive Detection and Follow-up Program Cooperative Group","year":"1982","unstructured":"Hypertensive Detection and Follow-up Program Cooperative Group. The effects of treatment on mild hypertension: results of the Hypertension Detection and Follow-up Program. N Engl J Med. 1982;307:976\u201380.","journal-title":"N Engl J Med."},{"key":"372_CR68","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1161\/01.CIR.82.5.1616","volume":"82","author":"Multiple Risk Factor Intervention Trial Research Group","year":"1990","unstructured":"Multiple Risk Factor Intervention Trial Research Group. Mortality after 10.5 years for hypertensive participants in the Multiple Risk Factor Intervention Trial. Circulation. 1990;82:1616\u201328. doi: 10.1161\/01.CIR.82.5.1616 .","journal-title":"Circulation."},{"key":"372_CR69","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1001\/jama.1991.03460240051027","volume":"265","author":"SHEP Cooperative Research Group","year":"1991","unstructured":"SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA. 1991;265:3255\u201364.","journal-title":"JAMA."},{"key":"372_CR70","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","volume":"288","author":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group","year":"2002","unstructured":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981\u201397.","journal-title":"JAMA."},{"key":"372_CR71","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMoa021716","volume":"348","author":"LM Wing","year":"2003","unstructured":"Wing LM, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348:583\u201392.","journal-title":"N Engl J Med."},{"key":"372_CR72","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","volume":"359","author":"K Jamerson","year":"2008","unstructured":"Jamerson K, Weber MA, Bakris GI, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417\u201328.","journal-title":"N Engl J Med."},{"key":"372_CR73","doi-asserted-by":"crossref","unstructured":"Ernst ME, Carter BL, Goerdt CJ, Steffenmeier JJG, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone in ambulatory and office blood pressure. Hypertension. 2006;47:352\u20138. doi: 10.1161\/01.HYP.0000203309.07140.d3 .","DOI":"10.1161\/01.HYP.0000203309.07140.d3"},{"key":"372_CR74","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/j.1751-7176.2010.00373.x","volume":"12","author":"ME Ernst","year":"2010","unstructured":"Ernst ME, Lund BC. Renewed interest in chlorthalidone: evidence from the Veterans Health Administration. J Clin Hypertens. 2010;12:927\u201334. doi: 10.1111\/j.1751-7176.2010.00373.x .","journal-title":"J Clin Hypertens."},{"key":"372_CR75","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1161\/01.HYP.0000179582.42830.1d","volume":"46","author":"C Saha","year":"2005","unstructured":"Saha C, Eckert GJ, Ambrosius WT, Chun TY, et al. Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension. 2005;46:481\u20137. doi: 10.1161\/01.HYP.0000179582.42830.1d .","journal-title":"Hypertension."},{"key":"372_CR76","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0895-7061(01)02342-1","volume":"15","author":"J Ouzan","year":"2002","unstructured":"Ouzan J, Perault C, Lincoff AM, Carre E, et al. The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens. 2002;15:333\u20139.","journal-title":"Am J Hypertens."},{"key":"372_CR77","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0895-7061(03)01032-X","volume":"16","author":"MK Nishizaka","year":"2003","unstructured":"Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003;16:925\u201330. doi: 10.1016\/s0895-7061(03)01032-x .","journal-title":"Am J Hypertens."},{"key":"372_CR78","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.amjhyper.2005.11.016","volume":"19","author":"Y Sharabi","year":"2006","unstructured":"Sharabi Y, Adler E, Shamis A, Nussinovitch N, et al. Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension. Am J Hypertens. 2006;19:750\u20135. doi: 10.1016\/j.amjhypertens.2005.11.016 .","journal-title":"Am J Hypertens."},{"key":"372_CR79","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.HYP.0000259805.18468.8c","volume":"49","author":"N Chapman","year":"2007","unstructured":"Chapman N, Dobson J, WilsonS Dahlof B, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007;49:839\u201345. doi: 10.1161\/01.HYP.0000259805.18468.8c .","journal-title":"Hypertension."},{"key":"372_CR80","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1097\/HJH.0b013e328014954d","volume":"25","author":"DA Lane","year":"2007","unstructured":"Lane DA, Shah S, Beevers DG. Low dose spironolactone in the management of resistant hypertension: a surveillance study. J Hypertens. 2007;25:891\u20134. doi: 10.1097\/HJH.0b013e.3280114954d .","journal-title":"J Hypertens."},{"key":"372_CR81","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1161\/HYPERTENSIONAHA.109.140988","volume":"55","author":"F Souza De","year":"2010","unstructured":"De Souza F, Muxfeldt E, Fiszman R, Salles G. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension. 2010;55:147\u201352. doi: 10.1161\/HYPERTENSIONAHA.109.140988 .","journal-title":"Hypertension."},{"key":"372_CR82","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1097\/HJH.0b013e32833d4c99","volume":"28","author":"B Alvarez-Alvarez","year":"2010","unstructured":"Alvarez-Alvarez B, Abad-Cardiel M, Fernandez-Cruz A, Martell-Claros N. Management of resistant arterial hypertension: role of spironolactone versus double blockage of the renin-angiotensin-aldosterone system. J Hypertens. 2010;28:2329\u201335. doi: 10.1097\/HJH.0b013e32833d4c99 .","journal-title":"J Hypertens."},{"key":"372_CR83","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/HYPERTENSIONAHA.111.169961","volume":"57","author":"J Vaclavik","year":"2011","unstructured":"Vaclavik J, Sedlak R, Plachy M, Navratil K, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized double-blind, placebo-controlled trial. Hypertension. 2011;57:1069\u201375. doi: 10.1161\/HYPERTENSIONAHA.111.169961 .","journal-title":"Hypertension."},{"key":"372_CR84","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1097\/HJH.0b013e3283638b1a","volume":"31","author":"CS Oxlund","year":"2013","unstructured":"Oxlund CS, Henriksen JE, Tarnow L, Schousboe K, et al. Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. J Hypertens. 2013;31:2094\u2013102. doi: 10.1097\/hjh.0b013e3283638b1a .","journal-title":"J Hypertens."},{"key":"372_CR85","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/jch.12051","volume":"15","author":"AD Karns","year":"2013","unstructured":"Karns AD, Bral JM, Hartman D, Peppard T, et al. Study of aldosterone synthetase inhibition as an add-on therapy in resistant hypertension. J Clin Hypertens. 2013;15:186\u201392. doi: 10.1111\/jch.12051 .","journal-title":"J Clin Hypertens."},{"issue":"1","key":"372_CR86","first-page":"75","volume":"22","author":"R Abolghasmi","year":"2011","unstructured":"Abolghasmi R, Taziki O. Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension. Saudi J Kidney Dis Transplant. 2011;22(1):75\u20138.","journal-title":"Saudi J Kidney Dis Transplant."},{"key":"372_CR87","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1161\/HYPERTENSIONAHA.107.103580","volume":"51","author":"JD Dietz","year":"2008","unstructured":"Dietz JD, Du S, Bolten CW, Payne MA, et al. A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. Hypertension. 2008;51:742\u20138. doi: 10.1161\/HYPERTENSIONAHA.107.103580 .","journal-title":"Hypertension."},{"key":"372_CR88","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejphar.2010.03.018","volume":"635","author":"H Kosaka","year":"2010","unstructured":"Kosaka H, Hirayama K, Yoda N, Sasaki K, et al. The L-, N- and T-type triple calcium channel blocker benidipine acts as an antagonist of mineralocorticoid receptor, a member of nuclear receptor family. Eur J Pharmacol. 2010;635:49\u201355. doi: 10.10016\/j.ejphar.2010.03.018 .","journal-title":"Eur J Pharmacol."},{"key":"372_CR89","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/HJH.0b013e3283599b6a","volume":"31","author":"G Colussi","year":"2012","unstructured":"Colussi G, Catena C, Sechi LA. Spironolactone, eplerenone, and the new aldosterone blockers in endocrine and primary hypertension. J Hypertens. 2012;31:3\u201315. doi: 10.1097\/HJH.0b013e3283599bba .","journal-title":"J Hypertens."},{"key":"372_CR90","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/nrcardio.2012.33","volume":"9","author":"L Paulis","year":"2012","unstructured":"Paulis L, Steckelings UM, Unger T. Key advances in antihypertensive treatment. Nat Rev Cardiol. 2012;9:276\u201385. doi: 10.1038\/nrcardio.2012.33 .","journal-title":"Nat Rev Cardiol."},{"key":"372_CR91","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.semnephrol.2014.04.008","volume":"34","author":"I Lazich","year":"2014","unstructured":"Lazich I, Bakris GL. Prediction and management of hyperkalemia across the spectrum of chronic kidney disease. Semin Nephrol. 2014;34:333\u20139. doi: 10.1016\/jsemnephrol.2014.04.008 .","journal-title":"Semin Nephrol."},{"key":"372_CR92","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1536\/ihj.54.88","volume":"54","author":"Y Yoshitoma","year":"2013","unstructured":"Yoshitoma Y, Kawanishi KI, Yamaguchi A, Sakurai SI, et al. Effectiveness of the direct renin inhibitor aliskerin in patients with resistant hypertension. Int Heart J. 2013;54:88\u201392.","journal-title":"Int Heart J."},{"key":"372_CR93","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1136\/bmj.e42","volume":"344","author":"Z Harel","year":"2012","unstructured":"Harel Z, Gilbert C, Wald R, Bell C, et al. The effect of combination treatment with aliskerin and blockers of the renin-angiotensin-aldosterone system on hyperkalemia and acute kidney injury: systematic review and meta-analysis. BMJ. 2012;344:e42. doi: 10.1136\/bmj.e42 .","journal-title":"BMJ."},{"issue":"1","key":"372_CR94","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/1074248413501018","volume":"19","author":"NR Robles","year":"2014","unstructured":"Robles NR, Cerezo I, Hernandez-Gallego R. Renin-angiotensin system blocking drugs. J Cardiovasc Pharmacol Ther. 2014;19(1):14\u201333. doi: 10.1177\/1074248413501018 .","journal-title":"J Cardiovasc Pharmacol Ther."},{"key":"372_CR95","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1161\/HYPERTENSIONAHA.110.157271","volume":"56","author":"L Amar","year":"2010","unstructured":"Amar L, Azizi M, Menard J, Peyrard S, et al. Aldosterone synthetase inhibition with LCI699. Hypertension. 2010;56:831\u20138. doi: 10.1161\/HYPERTENSIONAHA.110.157271 .","journal-title":"Hypertension."},{"key":"372_CR96","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1161\/CIRCULATIONAHA.111.029892","volume":"124","author":"DA Calhoun","year":"2011","unstructured":"Calhoun DA, white WB, Krum H, Guo W, et al. Effects of a novel aldosterone synthetase inhibitor for treatment of primary hypertension: results of a randomized double-blind placebo and active-controlled phase 2 trial. Circulation. 2011;124:1945\u201355. doi: 10.1161\/CIRCULATIONAHA.111.029892 .","journal-title":"Circulation"},{"issue":"4","key":"372_CR97","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1177\/1470320313513408","volume":"14","author":"M Monge","year":"2013","unstructured":"Monge M, Lorthioir A, Bobrie G, Azizi M. New drug therapies interfering with the renin-angiotensin-aldosterone system for resistant hypertension. J Renin Angiotensin Aldosterone Syst. 2013;14(4):285\u20139. doi: 10.1177\/1470320313513408 .","journal-title":"J Renin Angiotensin Aldosterone Syst."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0372-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-015-0372-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0372-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T03:46:42Z","timestamp":1566445602000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-015-0372-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,19]]},"references-count":97,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["372"],"URL":"https:\/\/doi.org\/10.1007\/s40265-015-0372-3","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,19]]}}}